AstraZeneca PLC's asthma rescue medication Airsupra has received the green light from US regulators, boosting the UK major's respiratory franchise which is feeling the pinch due to declining revenues of the blockbuster Symbicort.
Airsupra Could Help Revive AstraZeneca's Respiratory Fortunes
Will Soften Impact Of Declining Symbicort Sales
The US Food and Drug Administration has approved AstraZeneca and Avillion’s respiratory drug Airsupra, making it the only rescue medication cleared for as-needed use to reduce risk of asthma exacerbations.
